Latest Biotech News

CMS launched a voluntary payment model to expand Medicare coverage of GLP‑1 weight‑loss drugs, aiming to broaden beneficiary access while testing new payment and utilization rules. The program,...

The FDA approved Omeros’s complement inhibitor Yartemlea as the first approved therapy for a severe and potentially fatal complication of hematopoietic stem cell transplants. Omeros secured...

Johnson & Johnson said it will discontinue development of the experimental eczema drug JNJ‑5939 (NM26), the asset it acquired for $1.25 billion in 2024, after the program failed to meet internal...

Biohaven reported that its potassium‑channel modulator missed primary endpoints in a Phase 2 trial for major depressive disorder, marking a second mid‑stage failure for the program. The company...

Researchers unveiled an intelligent design framework for adeno‑associated virus (AAV) vectors that respond to tumor microenvironment cues to improve targeting and infiltration into tumors. The...

A new body of work positioned nanovaccine platforms as next‑generation immunotherapies for hepatocellular carcinoma (HCC), detailing nanoparticle formulations that deliver tumor antigens and...

SpatialBench introduced a suite of 146 verifiable problems drawn from real spatial biology workflows to benchmark agents that analyze spatial transcriptomics and imaging data. The authors argue...

New research delivered fresh mechanistic and clinical insights into neurotoxic events associated with CAR‑T cell therapies, identifying pathways and biomarkers linked to neurological adverse...

Akbari and colleagues reported that co‑encapsulating cisplatin with the natural compound silibinin in biodegradable PLGA nanoparticles improved tumor uptake and anti‑cancer efficacy in preclinical...

A review explored targeted protein degradation (TPD) as a transformative therapeutic modality while flagging potential broader biological and ecological impacts. Authors (Yue, He, Hou et al.)...

CMS launched a voluntary payment model intended to expand Medicare coverage of GLP‑1 weight‑loss drugs for eligible beneficiaries. The administration designed the pilot to test payment approaches...

The FDA approved Yartemlea, Omeros’s complement‑system drug, for a severe and potentially fatal complication of hematopoietic stem cell transplants, marking the first regulator‑confirmed therapy...

Johnson & Johnson terminated development of its experimental eczema candidate JNJ‑5939 (NM26) after a Phase 2 trial did not meet efficacy thresholds, ending hopes tied to the $1.25 billion...

Researchers published a framework for engineering adeno‑associated virus (AAV) vectors that dynamically respond to features of the tumor microenvironment to enhance tumor targeting and...

Researchers reported progress on nanovaccine platforms tailored to hepatocellular carcinoma (HCC), demonstrating nanoparticle‑mediated antigen presentation and immune activation in preclinical...

SpatialBench, a new benchmark suite, evaluates computational agents on 146 verifiable spatial biology problems drawn from real analysis workflows across five platforms (Vizgen MERFISH, 10x Visium,...

Recent advances summarize mechanisms behind CAR‑T cell therapy neurotoxicity, consolidating clinical signals, imaging correlates, and biomarker profiles to refine risk stratification and...

Researchers reported therapeutic approaches aimed at reversing multidrug resistance (MDR) in lung cancer, including novel small molecules, combination regimens, and delivery systems that restore...

A research team demonstrated that encapsulating cisplatin with silibinin inside biodegradable PLGA polymeric nanoparticles improves antitumor efficacy in cervical cancer models compared with free...

A comprehensive review examined the biomedical promise and broader effects of targeted protein degradation (TPD), surveying therapeutic potential, off‑target risks, and ecological considerations....